HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · IEX Real-Time Price · USD
18.56
+0.55 (3.05%)
At close: Jul 26, 2024, 4:00 PM
18.00
-0.56 (-3.02%)
After-hours: Jul 26, 2024, 7:16 PM EDT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,988 employees as of December 31, 2023. The number of employees decreased by 37 or -1.83% compared to the previous year.
Employees
1,988
Change (1Y)
-37
Growth (1Y)
-1.83%
Revenue / Employee
$421,529
Profits / Employee
$50,694
Market Cap
3.23B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,988 | -37 | -1.83% |
Dec 31, 2022 | 2,025 | 266 | 15.12% |
Dec 31, 2021 | 1,759 | 479 | 37.42% |
Dec 31, 2020 | 1,280 | 427 | 50.06% |
Dec 31, 2019 | 853 | 139 | 19.47% |
Dec 31, 2018 | 714 | 124 | 21.02% |
Dec 31, 2017 | 590 | 27 | 4.80% |
Dec 31, 2016 | 563 | 112 | 24.83% |
Dec 31, 2015 | 451 | 102 | 29.23% |
Dec 31, 2014 | 349 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Amedisys | 19,000 |
ICU Medical | 14,000 |
Azenta | 3,500 |
Oscar Health | 2,400 |
Inari Medical | 1,300 |
GoodRx Holdings | 694 |
ACADIA Pharmaceuticals | 598 |
Amicus Therapeutics | 517 |
HCM News
- 23 days ago - HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status - GlobeNewsWire
- 4 weeks ago - HUTCHMED to Announce 2024 Half-Year Financial Results - GlobeNewsWire
- 4 weeks ago - Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 - GlobeNewsWire
- 5 weeks ago - HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda - GlobeNewsWire
- 5 weeks ago - HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology - GlobeNewsWire
- 7 weeks ago - HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China - GlobeNewsWire
- 7 weeks ago - HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting - GlobeNewsWire